Seattle Genetics cordially invites you to an educational program
FRONTLINE ADVANCEMENTS: CLINICAL DATA OVERVIEW OF ECHELON-1
Join us to review data from ECHELON-1, a superiority trial comparing ADCETRIS+AVD to ABVD. This trial introduces a bleomycin-free regimen for adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL).1 We’ll also discuss the latest data from the North American subset analyses.
FEATURED SPEAKER Andrew Evens, DO, MSc Rutgers Cancer Institute of NJ New Brunswick, New Jersey
DATE/TIME 9/24/20 - 3:00-4:00pm EDT – Dr. Evens
10/6/20 - 2:00-3:00pm EDT – Dr. Evens
10/27/20 - 1:00-2:00pm EDT – Dr. Evens
11/12/20 - 12:00-1:00pm EDT - Dr. Evens
Healthcare professionals including hematologist oncologists, medical oncologists, pharmacists, PAs, NPs, and RNs are encouraged to participate in this valuable dialogue.
RSVP To RSVP or for information regarding ADCETRIS, contact your local Seattle Genetics Account Manager,
Register at: www.SeaGenvirtualseries.com